You have landed on a page of the archived Cochrane Community website. This site is not being maintained or updated.

If you are looking for Cochrane Review evidence, please visit Cochrane’s evidence page.

If you are a Cochrane contributor looking for Community resources, please visit the new Cochrane Community website.

Long-acting beta2-agonists for chronic obstructive pulmonary disease

Warning: Parameter 2 to onepixelout_swftools_flashvars() expected to be a reference, value given in module_invoke() (line 476 of /var/www/archive/includes/

To browse Podcasts by topic, please visit the new Cochrane Summaries site here

Chronic obstructive pulmonary disease is a common condition and causes the death of millions of people worldwide every year, and the Cochrane Airways Group has already produced several reviews. In October 2013, their collection has been added to with a review of the effects of long-acting beta-agonists. The lead author, Kayleigh Kew from St George’s Hospital in London England, tells us more.

Play Now!

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Download [mp3]  | Read Review
Updated on: October 29, 2013, 12:08

Comments for improvement or correction are welcome.